Literature DB >> 11157669

Role of phasic dynamism of p38 mitogen-activated protein kinase activation in ischemic preconditioning of the canine heart.

S Sanada1, M Kitakaze, P J Papst, K Hatanaka, H Asanuma, T Aki, Y Shinozaki, H Ogita, K Node, S Takashima, M Asakura, J Yamada, T Fukushima, A Ogai, T Kuzuya, H Mori, N Terada, K Yoshida, M Hori.   

Abstract

Although ischemic stress, including ischemic preconditioning (IP), activates p38 mitogen-activated protein kinase (MAPK), the relationship between p38 MAPK activation and the underlying cellular mechanisms of cardioprotection by IP is not verified in vivo. We examined the effects of the selective p38 MAPK inhibition on the cardioprotective effect of IP in the open-chest dogs. The coronary artery was occluded 4 times for 5 minutes, separated by 5 minutes of reperfusion (IP) followed by 90 minutes of occlusion and 6 hours of reperfusion. We infused SB203580 into the coronary artery during IP and 1 hour of reperfusion, during IP alone, and during sustained ischemia in the IP group. p38 MAPK activity markedly increased during IP but did not additionally increase at the onset of ischemia and was even attenuated at 15 minutes of sustained ischemia, and heat-shock protein (HSP) 27 was phosphorylated and translocated from cytosol to myofibril or nucleus without affecting total protein level at the onset of ischemia compared with the control group. SB203580 treatment (1 micromol/L) only during IP blunted the infarct size limitation by IP (37.3+/-6.3% versus 7.4+/-2.1% in the IP group, P:<0.01) and attenuated either phosphorylation or translocation of HSP27 during IP. Although the SB203580 treatment throughout the preischemic and postischemic periods had no significant effect on infarct size (33.3+/-9.4%) in this model, treatment with SB203580 only during ischemia partially mimicked the infarct size limitation by IP (26.8+/-3.5%). Thus, transient p38 MAPK activation during ischemic preconditioning mainly mediates the cardioprotection followed by HSP27 phosphorylation and translocation in vivo in the canine heart.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11157669     DOI: 10.1161/01.res.88.2.175

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  21 in total

Review 1.  Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale.

Authors:  Beth A Rose; Thomas Force; Yibin Wang
Journal:  Physiol Rev       Date:  2010-10       Impact factor: 37.312

2.  SIRT1 modulates MAPK pathways in ischemic-reperfused cardiomyocytes.

Authors:  Matteo Becatti; Niccolò Taddei; Cristina Cecchi; Niccolò Nassi; Paolo Antonio Nassi; Claudia Fiorillo
Journal:  Cell Mol Life Sci       Date:  2012-02-05       Impact factor: 9.261

3.  Hepatocyte cytoskeleton during ischemia and reperfusion--influence of ANP-mediated p38 MAPK activation.

Authors:  Melanie Keller; Alexander L Gerbes; Stefanie Kulhanek-Heinze; Tobias Gerwig; Uwe Grutzner; Nico van Rooijen; Angelika M Vollmar; Alexandra K Kiemer
Journal:  World J Gastroenterol       Date:  2005-12-21       Impact factor: 5.742

4.  Effect of atrial natriuretic peptide on ischemia-reperfusion injury in a porcine total hepatic vascular exclusion model.

Authors:  Katsumi Kobayashi; Kiyohiro Oshima; Masato Muraoka; Takahiko Akao; Osamu Totsuka; Hisashi Shimizu; Hiroaki Sato; Kazumi Tanaka; Kenjiro Konno; Koshi Matsumoto; Izumi Takeyoshi
Journal:  World J Gastroenterol       Date:  2007-07-07       Impact factor: 5.742

5.  Characterization of hsp27 kinases activated by elevated aortic pressure in heart.

Authors:  Benoit Boivin; Maya Khairallah; Raymond Cartier; Bruce G Allen
Journal:  Mol Cell Biochem       Date:  2012-08-10       Impact factor: 3.396

6.  MMI-0100 inhibits cardiac fibrosis in myocardial infarction by direct actions on cardiomyocytes and fibroblasts via MK2 inhibition.

Authors:  Lei Xu; Cecelia C Yates; Pamela Lockyer; Liang Xie; Ariana Bevilacqua; Jun He; Cynthia Lander; Cam Patterson; Monte Willis
Journal:  J Mol Cell Cardiol       Date:  2014-10-01       Impact factor: 5.000

Review 7.  Role of p38 inhibition in cardiac ischemia/reperfusion injury.

Authors:  Sarawut Kumphune; Siriporn Chattipakorn; Nipon Chattipakorn
Journal:  Eur J Clin Pharmacol       Date:  2011-12-29       Impact factor: 2.953

Review 8.  Mitogen-activated protein kinases: a new therapeutic target in cardiac pathology.

Authors:  Tána Ravingerová; Miroslav Barancík; Monika Strnisková
Journal:  Mol Cell Biochem       Date:  2003-05       Impact factor: 3.396

9.  The activation of p38 alpha, and not p38 beta, mitogen-activated protein kinase is required for ischemic preconditioning.

Authors:  Pierre Sicard; James E Clark; Sebastien Jacquet; Shahrooz Mohammadi; J Simon C Arthur; Stephen J O'Keefe; Michael S Marber
Journal:  J Mol Cell Cardiol       Date:  2010-02-25       Impact factor: 5.000

10.  Sulindac confers high level ischemic protection to the heart through late preconditioning mechanisms.

Authors:  Ian Moench; Howard Prentice; Zach Rickaway; Herbert Weissbach
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-02       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.